CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Review uri icon

Overview

abstract

  • Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.

publication date

  • January 15, 2015

Identity

PubMed Central ID

  • PMC4295550

Digital Object Identifier (DOI)

  • 10.3389/fonc.2014.00385

PubMed ID

  • 25642417

Additional Document Info

volume

  • 4